http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022092649-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4b5a91fcfdbeaa99fa93f26da82b196a
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
filingDate 2021-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b1df170107c859f142abaa154060f2c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8951ee7b5bd2d4004e0fc857cc45412b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56eb7f31d6509c27df98d0dede7af5a3
publicationDate 2022-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2022092649-A1
titleOfInvention Composition for enhancing tumor penetration of anticancer drug, comprising losartan as active ingredient, and use thereof
abstract The present invention relates to a composition for enhancing tumor penetration of an anticancer drug, comprising losartan as an active ingredient, and a use thereof. In the composition, losartan decomposes collagen and hyaluronic acid, which are main components of the extracellular matrix, to enhance the penetration of various anticancer drugs, including an antibody for cancer treatment, into the center of a tumor and uniformly distribute the various anticancer drugs, thereby improving a cancer treatment effect of an anticancer drug. Therefore, according to the present invention, by using combination therapy of losartan and an anticancer drug including an antibody for cancer treatment, penetration of the anticancer drug into the center of tumor can be enhanced, thereby making it possible to treat cancer more effectively.
priorityDate 2020-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20160038524-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60953
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5453
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399412
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226408069
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396322
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2187
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393254
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226397750
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226425017
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6442177
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12447
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60750
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11105
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3005573
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412125
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3961
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226400582
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID121841
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396689
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60198
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396389
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398849
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60838
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396105

Total number of triples: 48.